Posted from: Monday, October 09, 2017 - 06:37 PM - Present

Generics Launched for Effient

August 15, 2017 – Two generics for Eli Lilly’s Effient (prasugrel) have been launched—the first manufactured by Mylan, and the second manufactured by Prasco. Prasugrel is indicated for treatment of patients with acute coronary syndrome who have unstable angina or non-ST-elevation myocardial infarction (MI), or patients with ST-elevation MI, to reduce the rate of thrombotic cardiovascular (CV) events, including stent thrombosis. Eligible patients must be managed with primary or delayed percutaneous coronary intervention (PCI).

Mylan will have 60 days of market exclusivity for its AB-rated generic to Effient. Prasco’s prasugrel product is an authorized generic for brand name Effient. Additional generic products are expected to be released once Mylan’s period of exclusivity has ended on October 14, 2017.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.


Last Updated Friday, September 20, 2019 - 03:33 PM.